Neurobiological terminates stroke drug and cuts jobs
This article was originally published in Scrip
Executive Summary
Neurobiological Technologies is terminating its most advanced product candidate, Viprinex (ancrod) a potential treatment for ischaemic stroke. The drug's Phase III trials were halted in December after an interim analysis showed that it failed to improve patient outcome when given within six hours of a stroke.